Ad-hoc | 28 November 2003 08:31

aap Implantate AG: Nine-month 2003 figures published

Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– aap Implantate AG: Nine-month 2003 figures published In the first nine months of the financial year 2003, the subdued business trend continued at aap Implantate AG, a specialist in artificial and biomedical implants for the muscular-skeletal organ system. Consolidated sales revenues to September 30, 2003 were, at EUR 8.7 million, around 15.5% down on the year. Restraint continued to characterize ordering behavior in Germany, and the revival of business in Asia on the basis of a purchase agreement already signed will only lead to positive sales stimuli at aap from the current quarter onward. Before special factors (acquisition-related depreciation and stock options) the company’s EBITDA in the first nine months totaled EUR 852,000 (previous year: EUR 2.027 million). The adjusted operating result amounted to minus EUR 589,000 and was therefore down on the previous year’s EUR 1.182 million. The DVFA/SG consolidated result before special factors in the reporting period was minus EUR 1.148 million (previous year: minus EUR 163,000) and DVFA/SG earnings per share were minus EUR 0.24 (previous year: minus EUR 0.03). Taking the above-mentioned special factors into account, the figures were as follows. EBITDA was EUR 852,000 (previous year: EUR 1.585 million) and the operating result was minus EUR 1.685 million (previous year: minus EUR 299,000). The DVFA/SG consolidated result was minus EUR 1.906 million (previous year: minus EUR 1.134 million) and DVFA/SG earnings per share were minus EUR 0.40 (previous year: minus EUR 0.24). end of ad-hoc-announcement (c)DGAP 28.11.2003 Issuer’s information/explanatory remarks concerning this ad-hoc-announcement: Four new products are seen as aap’s growth drivers in the quarters ahead. The European approval of the company’s newly developed synthetic bone substitute PerOssal will further extend its competence in orthobiology. aap plans to expand its endoprosthetics product portfolio before the year is out by launching its new products AEQUOS and VarioFit. The positive response to aap’s innovative stable-angle plates for treating fractures of the upper and lower arm given by specialists at both this year’s German Orthopedists’ Congres and at the Medica trade fair is seen as confirmation of the market prospects of this new development in osteosynthesis too. ——————————————————————————– WKN: 506660; ISIN: DE0005066609; Index: Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin- Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart 280831 Nov 03